Search results for "postprandial hyperglycemia"

showing 2 items of 2 documents

Postprandial Hyperglycemia Is Associated With White Matter Hyperintensity and Brain Atrophy in Older Patients With Type 2 Diabetes Mellitus

2018

Type 2 diabetes mellitus is associated with neurodegeneration and cerebrovascular disease. However, the precise mechanism underlying the effects of glucose management on brain abnormalities is not fully understood. The differential impacts of glucose alteration on brain changes in patients with and without cognitive impairment are also unclear. This cross-sectional study included 57 older type 2 diabetes patients with a diagnosis of Alzheimer's disease (AD) or normal cognition (NC). We examined the effects of hypoglycemia, postprandial hyperglycemia and glucose fluctuations on regional white matter hyperintensity (WMH) and brain atrophy among these patients. In a multiple regression analysi…

Agingmedicine.medical_specialtyendocrine system diseasesCognitive Neuroscience030209 endocrinology & metabolismDiseaseType 2 diabetesHypoglycemialcsh:RC321-57103 medical and health sciences0302 clinical medicineAtrophyDiabetes mellitusInternal medicineMedicineCognitive declinepostprandial hyperglycemialcsh:Neurosciences. Biological psychiatry. Neuropsychiatrybusiness.industrywhite matter hyperintensityType 2 Diabetes Mellitusmedicine.diseasePostprandialdiabetes mellitusCardiologybusinessAlzheimer’s diseasebrain atrophy030217 neurology & neurosurgeryFrontiers in Aging Neuroscience
researchProduct

POSTPRANDIAL HYPERGLYCEMIA IS A DETERMINANT OF PLATELET ACTIVATION IN EARLY 2 DIABETES MELLITUS

2010

BACKGROUND: Chronic hyperglycemia is a major contributor to in vivo platelet activation in diabetes mellitus. OBJECTIVES: To evaluate the effects of acarbose, an alpha-glucosidase inhibitor, on platelet activation and its determinants in newly diagnosed type 2 diabetic patients. METHODS: Forty-eight subjects (26 males, aged 61 +/- 8 years) with early type 2 diabetes (baseline hemoglobin A(1c) < or = 7% and no previous hypoglycemic treatment) were randomly assigned to acarbose up to 100 mg three times a day or placebo, and evaluated every 4 weeks for 20 weeks. The main outcome measures were urinary 11-dehydro-thromboxane (TX)B(2) (marker of in vivo platelet activation) and 8-iso-prostaglandi…

Blood GlucoseMaleTime FactorsSettore MED/09 - Medicina InternaDinoprostpostprandial hyperglycemia; platelet activationMedicineEnzyme InhibitorsSettore MED/49 - Scienze Tecniche Dietetiche Applicatepostprandial hyperglycemiaAcarboseplateletHemoglobin AHematologyMiddle AgedPostprandial PeriodP-SelectinPostprandialTreatment OutcomeC-Reactive ProteinItalyFemaleBiological MarkersAcarboseType 2medicine.drugacarbose platelet activation postprandial hyperglycemia type 2 diabetes mellitusmedicine.medical_specialtySettore BIO/14 - FARMACOLOGIAUrinary systemCD40 LigandGlycosylatedArginineExcretionBlood Glucose; Time Factors; Lipid Peroxidation; Middle Aged; Hemoglobin A Glycosylated; Postprandial Period; Diabetes Mellitus Type 2; Enzyme Inhibitors; Hypoglycemic Agents; P-Selectin; Platelet Activation; Aged; CD40 Ligand; Treatment Outcome; Male; Female; Thromboxane B2; Dinoprost; Italy; Arginine; Acarbose; Double-Blind Method; Humans; Biological Markers; Hyperglycemia; alpha-Glucosidases; C-Reactive ProteinDouble-Blind MethodInternal medicineDiabetes mellitusDiabetes MellitusHypoglycemic AgentsHumansGlycoside Hydrolase InhibitorsPlatelet activationGlycemicAgedGlycated Hemoglobinbusiness.industryType 2 Diabetes Mellitusalpha-Glucosidasesmedicine.diseasePlatelet ActivationThromboxane B2EndocrinologyDiabetes Mellitus Type 2HyperglycemiaLipid PeroxidationbusinessBiomarkers
researchProduct